Journal: Therapeutic Advances in Drug Safety
Article Title: Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
doi: 10.1177/2042098620937899
Figure Lengend Snippet: Published trials on esketamine nasal spray.
Article Snippet: Morrison et al ., 2018, Netherlands [ ClinicalTrials.gov identifier: NCT02094378] , Phase I, randomised, double-blind, placebo-controlled, 2-way crossover study, N = 24 , 19–49 years June 2014 to August 2014 Computer-generated randomisation , 50.0 , Body mass index 18–30 kg/m 2 Body weight: ⩾45kg , • Screening phase (up to 3 weeks), • Double-blind treatment phase (2 weeks) • Post treatment (follow-up) phase (1-week) , Treatment sequence 1 ( n = 12): intranasal esketamine 84 mg Treatment sequence 2 ( n = 12): intranasal placebo , Treatment sequence 1: intranasal placebo Treatment sequence 2: intranasal esketamine 84 mg , Primary : five tests of Cogstate® computerised test battery assessed at 1 h pre-dose and 40 min, 2, 4, and 6-hour post-dose. Secondary : Mental Effort Scale, KSS, and safety and tolerability (TEAEs, C-SSRS, MOAA/S, BPRS+, and CADSS) , Safety and efficacy of intranasal esketamine on cognitive functioning in healthy participants. Esketamine was associated with cognitive performance decline.
Techniques: Sequencing, Functional Assay